Community Acquired Bacterial Pneumonia (CABP) Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Persistent and High Prevalence of Pneumonia, Necessitating Effective and Evolving Therapeutic Strategies
   3. Market Restraints
      1. Antibiotic Resistance Challenges
   4. Market Opportunity
      1. Development and Commercialization of Advanced Vaccines Tailored to Address a Broader Spectrum of Bacterial Pathogens Causing Pneumonia
   5. Market Trends
      1. Antibiotic Stewardship Initiatives
      2. Advancements in Diagnostics
5. MARKET SEGMENTATION
   1. By Dose Form
      1. Solution
      2. Tablet
   2. By Drug Class
      1. Pleuromutilin
      2. Cephalosporin
      3. Glycylcycline
      4. Oxazolidinone
      5. Ketolide
   3. By Route of Administration
      1. Oral
      2. Intravenous
   4. By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
   5. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. Actavis Generics
      2. Allergan Plc.
      3. Cumberland Pharmaceuticals Inc.
      4. Cubist Pharmaceuticals LLC (Merck)
      5. Combioxin
      6. Eagle Pharmaceuticals Inc.
      7. Merck Sharp & Dohme Inc.
      8. Melinta Therapeutics
      9. Nabriva Therapeutics
      10. Pfizer Inc.
      11. Paratek Pharmaceuticals
      12. TiGenix
      13. Theravance Biopharma Inc.
      14. Shionogi Inc.
      15. Wakunaga Pharmaceutical Co. Ltd.

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global Community Acquired Bacterial Pneumonia (CABP) market?

The global market of Community Acquired Bacterial Pneumonia (CABP) is projected to reach USD 8.30 Bn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global Community Acquired Bacterial Pneumonia (CABP) market?

The global Community Acquired Bacterial Pneumonia (CABP) market has an estimated annual growth rate of 5.2%.

Q.3. What are the recent trends of Community Acquired Bacterial Pneumonia (CABP) market?

Antibiotic stewardship initiatives and advancements in diagnosticsis one of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in Community Acquired Bacterial Pneumonia (CABP)?

The major companies profiled in this report include Actavis Generics, Allergan Plc., Cumberland Pharmaceuticals Inc., Cubist Pharmaceuticals LLC (Merck), Combioxin, Eagle Pharmaceuticals Inc., Merck Sharp & Dohme Inc., Melinta Therapeutics, Nabriva Therapeutics, Pfizer Inc., Paratek Pharmaceuticals, TiGenix, Theravance Biopharma Inc., Shionogi Inc., Wakunaga Pharmaceutical Co. Ltd. among others.

Q.5. Which is the largest regional market in the Community Acquired Bacterial Pneumonia (CABP)?

North America is the largest regional market for Community Acquired Bacterial Pneumonia (CABP).